Literature DB >> 20061925

Creatinine reduction ratio: a useful marker to identify medium and high-risk renal transplants.

Enric Vilar1, Mira Varagunam, Muhammad M Yaqoob, Martin Raftery, Raj Thuraisingham.   

Abstract

INTRODUCTION: Delayed graft function (DGF) has a major impact on long-term renal transplant survival. However, it is a diagnosis made retrospectively with little opportunity to modify treatment protocols. A classification based on creatinine reduction ratio between days 1 and 2 (CRR2) suggests that patients with CRR2 less than or equal to 30% (nondialysis requiring DGF [ND-DGF]) have similar outcomes to those with dialysis-requiring delayed graft function (D-DGF). We retrospectively applied this definition in our cohort of patients to examine outcomes.
METHODS: We studied the association between CRR2 and graft outcomes in all 367 patients transplanted between 1996 and 2004 at our center. Patients were divided into the following three groups: IGF (immediate graft function; CRR2 >30%), D-DGF, and ND-DGF. Mean follow-up was 4.2 years.
RESULTS: IGF accounted for 36% of patients, D-DGF for 22%, and ND-DGF for 42%. CRR2 was inversely correlated with serum creatinine on days 7, 30, 90, and 365 (r ranging from -0.65 to -0.22, P<0.001). Graft survival at 5 years was 98% (IGF), 74% (D-DGF), and 89% (ND-DGF). There was a significant difference in graft survival between IGF and D-DGF (P<0.001) and IGF and ND-DGF (P=0.005). In a multivariate analysis adjusting for recipient age and sex, donor age and sex, and human leukocyte antigen mismatch, graft failure was 2.4 times more likely to occur in patients with D-DGF than those with ND-DGF(P=0.02).
CONCLUSIONS: Our study shows CRR2 influences long-term graft outcomes. Unlike the original description, patients with ND-DGF carry an intermediate risk and perhaps should be considered on day 2 for alternative treatment protocols.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061925     DOI: 10.1097/TP.0b013e3181be3dd1

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

Review 1.  Advances in Detection of Kidney Transplant Injury.

Authors:  Sanjeeva Herath; Jonathan Erlich; Amy Y M Au; Zoltán H Endre
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

2.  Interleukin-8 transcripts in mononuclear cells determine impaired graft function after kidney transplantation.

Authors:  Christoffer Borst; Shengqiang Xia; Claus Bistrup; Martin Tepel
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

3.  Increased resistin in brain dead organ donors is associated with delayed graft function after kidney transplantation.

Authors:  Simona Oltean; Rille Pullerits; Anne Flodén; Michael Olausson; Mihai Oltean
Journal:  J Transl Med       Date:  2013-09-26       Impact factor: 5.531

4.  Protocol of a randomised controlled, open-label trial of ex vivo normothermic perfusion versus static cold storage in donation after circulatory death renal transplantation.

Authors:  Sarah A Hosgood; Kourosh Saeb-Parsy; Colin Wilson; Christopher Callaghan; Dave Collett; Michael L Nicholson
Journal:  BMJ Open       Date:  2017-01-23       Impact factor: 2.692

5.  Kinetic GFR Outperforms CKD-EPI for Slow Graft Function Prediction in the Immediate Postoperative Period Following Kidney Transplantation.

Authors:  Jonathan Dash; Thomas Verissimo; Anna Faivre; Lena Berchtold; Thierry Berney; Jérôme Pugin; Sophie de Seigneux; David Legouis
Journal:  J Clin Med       Date:  2020-12-10       Impact factor: 4.241

6.  Association of pre-transplant statin use with delayed graft function in kidney transplant recipients.

Authors:  Janske Reiling; David W Johnson; Peter S Kruger; Peter Pillans; Daryl R Wall
Journal:  BMC Nephrol       Date:  2012-09-17       Impact factor: 2.388

7.  Association of Slow Graft Function with Long-Term Outcomes in Kidney Transplant Recipients.

Authors:  Connie J Wang; Ahmad Tuffaha; Milind A Phadnis; Jonathan D Mahnken; James B Wetmore
Journal:  Ann Transplant       Date:  2018-04-03       Impact factor: 1.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.